On a quest to bring its multiple myeloma antibody-drug conjugate (ADC) Blenrep back to the U.S. | Members of the FDA's Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side ...

A group of independent advisors to the U.S. Food and Drug Administration (FDA) on Thursday voted against the approval of a combination drug regimen involving GSK’s (NYSE:GSK) blood cancer medicine ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

Deutsche Bank analyst Emmanuel Papadakis reiterated a Hold rating on GlaxoSmithKline today and set a price target of p1,450.00. The company’s shares opened today at p1,392.00. D ...

London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease, from Boston Pharmaceuticals ...

In April, the major pharma giants in the mergers and acquisitions (M&As) space were Novartis and Merck. Last month, however, the big names that announced multimillion-dollar buyouts were GSK, Sanofi, ...

GSK is also set to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2B in cash.

For the deal, GSK will make an upfront payment of $1.2 billion to Boston Pharmaceuticals, with the latter also being entitled to potential milestone payments of $800 million.

GSK has announced a $1.2 billion deal to acquire efimosfermin alfa from Boston Pharmaceuticals, writes John George for the Philadelphia Business Journal. The Montco-based company promised up to $800 ...